How to Treat Bladder Cancer in 2025 with Dr. Joaquim Bellmunt

Join Drs. Rahul & Rohit Gosain in this insightful episode of the Oncology Brothers podcast as they continue their treatment algorithm series, focusing on the rapidly evolving landscape of bladder cancer. They are joined by Dr. Joaquim Bellmunt, a medical oncologist and director of bladder cancer at the Dana-Farber Cancer Institute, who shares his expertise on the latest treatment paradigms for both muscle invasive and non-muscle invasive bladder cancer.

In this episode, you'll learn about:
•⁠  ⁠The distinction between muscle invasive and non-muscle invasive bladder cancer and their respective treatment approaches.
•⁠  ⁠The role of BCG treatment and emerging options for BCG-refractory disease.
•⁠  ⁠The significance of the NIAGARA trial and its implications for neoadjuvant chemotherapy and perioperative immunotherapy.
•⁠  ⁠Current strategies for managing muscle invasive bladder cancer, including the use of cisplatin-based therapies and the introduction of immunotherapy.
•⁠  ⁠Insights into the metastatic space, including the use of enfortumab vedotin (EV) and pembrolizumab, and the importance of next-generation sequencing (NGS) in treatment decisions.
•⁠  ⁠Key side effects to monitor with various treatments and the importance of maintaining quality of life for patients.

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information.

YouTube: https://youtu.be/apUp2-BkgWQ

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/
 
Don't forget to like, share, and subscribe for more discussions on cancer treatment algorithms!